Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial.
Atherogenic index
Glimepiride
Irisin
Omega-3
Sirtuin-1
T2DM
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
25 Nov 2023
25 Nov 2023
Historique:
received:
25
05
2023
accepted:
14
11
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
Type 2 diabetes mellitus (T2DM) is caused by insulin resistance or tissue insensitivity to insulin, as well as relative insulin insufficiency. Diabetes that is uncontrolled for an extended period of time is linked to substantial comorbidities and organ damage. The purpose of the current study is to assess the effect of coadministration of omega-3 fatty acids with glimepiride on blood glucose, lipid profile, serum irisin, and sirtuin-1 levels in T2DM patients. This clinical trial involved 70 type 2 diabetic patients randomly assigned to glimepiride 3 mg with either omega-3 capsules contained fish oil 1000 mg, 13% of eicosapentaenoic acid (EPA) and 9% docosahexaenoic acid (DHA) (omega-3 group, n = 35) or placebo capsules contained corn oil and linoleic acid (control group, n = 35) daily for three months. Blood samples were obtained at the start of the study and 12 weeks later for biochemical examination of HbA1c%, FBG, fasting insulin, and lipid profile. In addition, the atherogenic index of plasma (AIP) was calculated. Human enzyme-linked immunosorbent assay (ELISA) kits were utilized for assessing serum irisin and sirtuin-1 levels before and after the intervention. Compared to the control group, omega-3 fatty acids decreased serum fasting blood glucose (FBG, p < 0.001), glycated hemoglobin percent (HbA1C%, p < 0.001), total cholesterol (TC, p < 0.001), triglycerides (TGs, p = 0.006), low density lipoprotein (LDL, p = 0.089), and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR, p = 0.021) after three months of intervention. However, a significant increase was reported in serum irisin and high density lipoprotein (HDL) between both groups after intervention (p = 0.026 and p = 0.007, respectively). The atherogenic index of plasma (AIP) increased in the control group but decreased in the omega-3 group, with significant differences between the two groups (p < 0.001). The present study found that supplementing with omega-3 fatty acids might dramatically enhance blood irisin levels, as well as improve glycemic control and lipid profile in type 2 diabetes mellitus patients using glimepiride. This study is registered on ClinicalTrials.gov under identifier NCT03917940 . (The registration date: April 17, 2019).
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Type 2 diabetes mellitus (T2DM) is caused by insulin resistance or tissue insensitivity to insulin, as well as relative insulin insufficiency. Diabetes that is uncontrolled for an extended period of time is linked to substantial comorbidities and organ damage. The purpose of the current study is to assess the effect of coadministration of omega-3 fatty acids with glimepiride on blood glucose, lipid profile, serum irisin, and sirtuin-1 levels in T2DM patients.
METHODS
METHODS
This clinical trial involved 70 type 2 diabetic patients randomly assigned to glimepiride 3 mg with either omega-3 capsules contained fish oil 1000 mg, 13% of eicosapentaenoic acid (EPA) and 9% docosahexaenoic acid (DHA) (omega-3 group, n = 35) or placebo capsules contained corn oil and linoleic acid (control group, n = 35) daily for three months. Blood samples were obtained at the start of the study and 12 weeks later for biochemical examination of HbA1c%, FBG, fasting insulin, and lipid profile. In addition, the atherogenic index of plasma (AIP) was calculated. Human enzyme-linked immunosorbent assay (ELISA) kits were utilized for assessing serum irisin and sirtuin-1 levels before and after the intervention.
RESULTS
RESULTS
Compared to the control group, omega-3 fatty acids decreased serum fasting blood glucose (FBG, p < 0.001), glycated hemoglobin percent (HbA1C%, p < 0.001), total cholesterol (TC, p < 0.001), triglycerides (TGs, p = 0.006), low density lipoprotein (LDL, p = 0.089), and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR, p = 0.021) after three months of intervention. However, a significant increase was reported in serum irisin and high density lipoprotein (HDL) between both groups after intervention (p = 0.026 and p = 0.007, respectively). The atherogenic index of plasma (AIP) increased in the control group but decreased in the omega-3 group, with significant differences between the two groups (p < 0.001).
CONCLUSION
CONCLUSIONS
The present study found that supplementing with omega-3 fatty acids might dramatically enhance blood irisin levels, as well as improve glycemic control and lipid profile in type 2 diabetes mellitus patients using glimepiride.
TRIAL REGISTRATION
BACKGROUND
This study is registered on ClinicalTrials.gov under identifier NCT03917940 . (The registration date: April 17, 2019).
Identifiants
pubmed: 38001474
doi: 10.1186/s12902-023-01511-2
pii: 10.1186/s12902-023-01511-2
pmc: PMC10675938
doi:
Substances chimiques
Blood Glucose
0
Fatty Acids, Omega-3
0
Fibronectins
0
glimepiride
6KY687524K
Glycated Hemoglobin
0
Insulin
0
Sirtuin 1
EC 3.5.1.-
Banques de données
ClinicalTrials.gov
['NCT03917940']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
259Informations de copyright
© 2023. The Author(s).
Références
Int J Endocrinol Metab. 2017 Jan 21;15(1):e40614
pubmed: 28835761
Am J Clin Nutr. 2000 May;71(5):1085-94
pubmed: 10799369
Nature. 2012 Jan 11;481(7382):463-8
pubmed: 22237023
EMBO J. 2004 Jun 16;23(12):2369-80
pubmed: 15152190
Rom J Intern Med. 2019 Sep 1;57(3):233-240
pubmed: 30901315
J Diabetes Complications. 2004 Nov-Dec;18(6):367-76
pubmed: 15531188
Adv Biomed Res. 2014 Jan 09;3:15
pubmed: 24600599
Vasc Health Risk Manag. 2012;8:463-72
pubmed: 23028231
Clin Ther. 2021 Jul;43(7):e230-e240
pubmed: 34103176
Appl Physiol Nutr Metab. 2020 Aug;45(8):805-811
pubmed: 31935118
Mar Drugs. 2021 Mar 26;19(4):
pubmed: 33810216
Lipids Health Dis. 2019 Jan 26;18(1):31
pubmed: 30684965
Front Endocrinol (Lausanne). 2019 Mar 27;10:187
pubmed: 30972029
Int J Epidemiol. 2014 Jun;43(3):655-65
pubmed: 24691951
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
J Diabetes Complications. 2020 May;34(5):107553
pubmed: 32014347
Arch Iran Med. 2017 Jan;20(1):28-33
pubmed: 28112528
Diabetes Care. 2009 Jul;32(7):1327-34
pubmed: 19502545
PLoS One. 2017 Apr 10;12(4):e0175498
pubmed: 28394923
Lipids Health Dis. 2012 Oct 30;11:142
pubmed: 23107305
Clin Biochem. 2001 Oct;34(7):583-8
pubmed: 11738396
Int J Endocrinol. 2013;2013:746281
pubmed: 24298283
Eur Heart J. 2012 Feb;33(4):436-43
pubmed: 21933782
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
BMC Public Health. 2014 Oct 04;14:1035
pubmed: 25280535
Clin Chem. 1973 May;19(5):476-82
pubmed: 4703655
Curr Med Chem. 2018;25(9):1002-1035
pubmed: 29110598
Clin Chem. 1974 Apr;20(4):470-5
pubmed: 4818200
Int J Gen Med. 2020 Dec 07;13:1395-1409
pubmed: 33324086
J Pharmacopuncture. 2017 Dec;20(4):235-242
pubmed: 30151293
Am J Clin Nutr. 2008 Jun;87(6):1981S-90S
pubmed: 18541599
N Engl J Med. 2012 Jul 26;367(4):309-18
pubmed: 22686415
Metabolites. 2021 Oct 28;11(11):
pubmed: 34822400
Diabetes. 2009 Dec;58(12):2718-25
pubmed: 19940235
Diabetes Metab J. 2020 Feb;44(1):78-90
pubmed: 31237134
Am J Clin Nutr. 2006 Sep;84(3):540-50
pubmed: 16960167
J Nutr. 2012 Mar;142(3):592S-599S
pubmed: 22279140
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Singapore Med J. 2013 Jul;54(7):387-90
pubmed: 23900468
J Clin Res Pediatr Endocrinol. 2017 Dec 30;9(Suppl 2):49-57
pubmed: 29280741
Clin Exp Med. 2022 May;22(2):301-310
pubmed: 34286397
Am J Clin Nutr. 2007 Dec;86(6):1670-9
pubmed: 18065585
Atherosclerosis. 1998 Apr;137(2):419-27
pubmed: 9622285
Diabetes Metab. 2002 Feb;28(1):20-6
pubmed: 11938024